What Vyvgart treats.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- Chronic inflammatory demyelinating polyneuropathy (CIDP, with Vyvgart Hytrulo)
The mechanism.
Vyvgart (efgartigimod) blocks the neonatal Fc receptor (FcRn), accelerating the breakdown of pathogenic IgG antibodies that drive myasthenia gravis. By specifically targeting harmful antibodies without broadly suppressing immunity, Vyvgart offers a more selective approach than older immunosuppressants.
Your Vyvgart infusion experience.
Vyvgart is given in cycles of 4 weekly infusions, with cycles repeated based on clinical response (typically every 8 to 12 weeks). Each infusion lasts 1 hour. Most patients notice meaningful improvement in muscle strength within the first cycle.
Insurance & out-of-pocket cost.
Vyvgart is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.